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ABSTRACT Hepatitis C virus (HCV) burdens injection drug users (IDUs) with prevalence
estimated from 60–100% compared to around 5% among noninjection drug users
(non-IDUs). We present preliminary data comparing the risk for HCV among IDUs and
non-IDUs to inform new avenues of HCV prevention and intervention planning. Two
cohorts, new IDUs (injecting ≤3 years) and non-IDUs (smoke/sniff heroine, crack or
cocaine≤10 years), ages 15–40, were street-recruited in New York City. Participants under-
went risk surveys and HCV serology at baseline and 6-month follow-up visits. Person-time
analysis was used to estimate annual HCV incidence. Of 683 non-IDUs, 653 were HCV
seronegative, 422 returned for at least 1 follow-up visit, and 1 became HCV seropositive.
Non-IDUs contributed 246.3 person-years (PY) yielding an annual incident rate of
0.4/100 PY (95% Confidence Interval [CI]=0.0-1.2). Of 260 IDUs, 114 were HCV sero-
negative, 62 returned for at least 1 follow-up visit, and 13 became HCV seropositive. IDUs
contributed 36.3 PY yielding an annual incidence rate of 35.9/100 PY (95%CI=19.1–61.2).
Among IDUs, HCV seroconverters tended to be younger (median age 25 vs. 28,
respectively), and inject more frequently (61.5% vs. 34.7%, respectively) than nonsero-
converters. These interim data suggest that IDUs may have engaged in high-risk practices
prior to being identified for prevention services. Preventing or at least delaying transition
into injection could increase opportunity to intervene. Identifying risk factors for transition
into injection could inform early prevention to reduce onset of injection and risk of HCV.
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Hepatitis C virus (HCV) continues to be highly prevalent among injection drug
users (IDUs), with prevalence estimates ranging from 60% to 100%. HCV prevalence
among noninjection (non-IDUs) remains low, typically around 5% in most studies.1–8
Reported incidence for HCV in IDUs typically ranges from 10–37/100 person-years in
the United States and abroad.9–18 Published reports have shown high HCV incidence
among recent-onset or “new” IDUs, with risk for HCV (and human immunodeficiency
virus [HIV]) highest during the early stages of an injecting career,4,12,16,17 although
some reported an increasing cumulative risk.19,20 This early high-risk period has been
identified as occurring as early as 4 months through the first 3 years of injection
drug use.11,12,17,21–23 This report presents preliminary data comparing the risk for
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HCV among IDUs and non-IDUs in New York City to inform new avenues of HCV
prevention and intervention planning. 
In August 2000, extensive street outreach (including neighborhood mapping of
high-risk neighborhoods) and screening of IDUs and non-IDUs began in Harlem
and South Bronx neighborhoods of New York City, with special emphasis on
enrollment of recent-onset (i.e., injecting 3 years or less before interview) or new
IDUs. The majority of study participants were identified and enrolled after August
2002. Participants in the IDU cohort were eligible if they were 15–40 years of age
and injected at least once in the past 2 months. Non-IDUs were eligible if they were
15–40 years of age, used heroin, crack, or cocaine 10 years or less, had no history of
injection drug use or presence of stigmata, and used drugs at least once per week in
the past 2 months. Study participants underwent baseline and 2-month follow-up
visits over a 12-month period; these visits included risk surveys and blood draws for
HCV serological testing. The institutional review boards at the New York Academy of
Medicine and the New York Blood Center approved this study protocol, and
informed consent was obtained from each study participant. 
HCV antibodies were detected by enzyme-linked immunosorbent assay (Ortho
HCV Version 2.0). Sera that were reactive on the first testing were retested in duplicate.
Repeatedly reactive samples were confirmed by strip immunoblot assay (Chiron
RIBA HCV 3.0 SIA). Participants returned 2 to 3 weeks later to learn their test
results and receive referrals for medical care and other health and social services. 
HCV seroconversion was determined by the presence of HCV antibody in
previously seronegative participants. Date of HCV seroconversion was estimated to
occur at the midpoint between the last seronegative visit and the first seropositive visit.
Person-time analysis was used to estimate HCV incidence among cohort members
who returned for follow-up. 
As of August 2003, there were 683 non-IDUs tested for anti-HCV; 653 were
HCV seronegative, 422 returned for at least one follow-up visit (mean follow-up
time 3 months), and 1 participant became HCV seropositive. Non-IDUs contributed
246.3 person-years of follow-up time, yielding an annual incident rate of 0.4 per
100 person-years. Among 260 IDUs tested, 114 IDUs tested HCV seronegative, 62
returned for at least one follow-up visit (mean follow-up time 3 months), with 13
becoming HCV seropositive (Table 1). IDUs contributed 36.3 person-years of follow-up
time, yielding an annual incidence rate of 35.9 per 100 person-years. Comparing HCV
seroconverters to nonseroconverters, median age was 25 versus 28 years, respectively
(Table 2). In terms of injection risk, a higher proportion of seroconverters reported
high injection frequency (inject at least daily vs. less than daily) than nonseroconverters,
61.5% versus 34.7%, respectively. Among HCV-seronegative participants at baseline,
at least one follow-up visit has been completed by 70% of IDUs and 73% of non-IDUs,
with follow-up continuing. 
TABLE 1. Comparison of HCV seroincidence rates between IDUs and non-IDUs in New York 
City, 2000–2003    
Cohort No. of HCV seroconverters HCV seroconversion risk, %* 
*Calculated as number of HCV seronconverters per 100 person-years.
95% Confidence interval†
†The 95% confidence interval for non-IDU incidence estimate was based on a Poisson distribution; no
assumption was made for the IDU incidence estimate confidence interval.
Non-IDU 1 0.4 (0.0–1.2) 
IDU 13 35.9 (19.1–61.2) 
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The noteworthy finding, based on this interim analysis, is that hepatitis C incidence
is dramatically higher in recent-onset IDUs than non-IDUs, even in the presence of
HIV prevention efforts, which have likely contributed to declining HIV rates among
IDUs.24–26 This suggests that, by the time an IDU has been identified for prevention
services, the IDU may have already engaged in high-risk practices such as unsafe
syringe use that may lead to HCV transmission. In part, this is likely because of the
high efficiency of HCV transmission indicated with increased HCV risk (as compared
with HIV risk) from indirect sharing practices (i.e., sharing cookers, cotton, or rinse
water).5,27,28 Thus, the same prevention efforts that have been able to affect HIV
transmission (which is less efficiently transmitted) among IDUs may not be effective
in preventing the transmission of HCV. 
It has also been suggested that safer injection practices, such as attending
syringe-exchange programs and not sharing injection equipment, may not be employed
during the start of an injecting career, suggesting that extant HIV prevention methods
may be less useful in the context of HCV.5.29–31 Thus, the limited efficacy of extant
prevention efforts coupled with the high incidence of HCV among young IDUs
emphasizes the need to expand prevention efforts. 
These preliminary findings must be interpreted with some caution given the
small sample size and relatively short follow-up period. It is also important to note
that potential sources of bias were therefore not adequately explored in this report
at this stage of the study. Namely, study retention as well as external validity may
have influenced the point estimates, causing over- or underestimation. Given that
data presented here reflect rates approximately midway through study completion
(with some fluctuation in follow-up rates), incidence rates could be unstable at this
time. Although larger studies of HCV risk in new or young IDUs are needed to
confirm these findings, it is not likely that the disparity in HCV risk between IDUs
and non-IDUs will ease, which is the primary focus of this report.7,23 
These results suggest that, if injection could be prevented or at least delayed to
increase opportunity to intervene with risk reduction messages, the burden of HCV
among IDUs could be substantially reduced. Therefore, identifying risk factors for
transition into injection could inform early prevention and intervention strategies
not only to reduce injection drug use, but also to curtail risk of HCV. While prior
noninjection drug use, particularly with heroin, cocaine, or crack, is a major risk
factor for transition into injection drug use,32–34 researchers have indicated that
there are subgroups of illicit drug users who do not transition into injection drug
use for fear of HIV and not wanting to be identified as an injector.35,36 It is therefore
conceivable that circumstances other than illicit noninjection drug use may be better
predictors of transition into injection (e.g., high-risk social networks, lack of social
TABLE 2. Age and injection frequency of IDUs stratified by HCV seroconversion status 
in New York City, 2000–2003   
  High injection frequency  
IDU seroconversion status (N =62)* 
*Total number of IDUs who followed-up.
Median age, years (range)† 
†Number (N) and proportion (%) who injected at least daily versus less than daily at baseline visit; P<.08.
N (%) Odds ratio‡
‡95% confidence interval = 0.9–10.6.
HCV seroconverters 25 (23–39) 8 (61.5) 3.01 
Non-HCV seronconverters 28 (17–40) 17 (34.7) 1.00 
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support, neighborhood characteristics, etc.). Identifying such factors so that messages
can be expanded to target high-risk non-IDUs regarding the risk of injection drug
use to prevent transition into injection is critical. 
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